Association Between VEGF-C and miRNA and Clinical Non-small Cell Lung Cancer and Esophagus Squamous Cell Carcinoma

NCT01240369 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2010-11-15

No results posted yet for this study

Summary

Lung cancer and esophageal cancer remain the leading causes of cancer death worldwide. The main problem is lack of effective tool in early detection that accounts for the poor outcome of cancer. Clinically, over 80% of patients with cancer were at late stage when they were diagnosed. Therefore, it is important for us to find the biomarker that serve as the early prediction of cancer.

The investigators have published that VEGFC over-expressed in non-small cell lung cancer. VEGFC plays a critical role in regulating motility of tumor cells, promotes proliferation of lymphatic endothelial cells and enhances migration and invasion. Investigator found that VEGFC over-expressed in the serum of esophageal cancer patients. Therefore, it is worthwhile to investigate the correlation between VEGFC, clinical lung cancer and esophageal cancer.

MicroRNAs (miRNAs) are conserved, endogenous, small, and noncoding RNA molecules of 21\~23 nucleotides that function as post-transcriptional gene regulators. Recent studies indicated that certain microRNAs reduced in cancer patients. Therefore it is important to investigate whether specific microRNA changed in certain kinds of cancer patients.

Conditions

  • VEGFC Protein in Serum
  • VEGFC Protein in Non Small Cell Lung Cancer
  • VEGFC Protein in ESCC
  • CTTN Protein in ESCC
  • miR326 in ESCC and Non Small Cell Lung Cancer

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01240369 on ClinicalTrials.gov